Pipeline

Rain has built a pipeline of targeted oncology therapies. For more information on each of our programs, please visit our Science page.

Program Overview

Program Indication Combo Strategy Preclinical
LO
IND ES
Dose Escalation
Ph 1a
Dose Expansion
Ph 1b
Ph 2
Pivotal
Ph 2b
Ph 3
RAIN-32
(DS-3032)
MDM2
WD / DD Liposarcoma 2021 Start
MDM2 Basket Study 2021 Start
AML: FLT3-ITD Quizartinib
Tarloxotinib
Pan-HER
NSCLC: HER2 Ex20
Basket: NRG1 / HER Fusions1
RAD52 Research Program PARP-relapsed. HRD+Tumors
BRCA-deficient tumors
Program Indication / Strategy Phase
RAIN-32
(DS-3032) MDM2
WD / DD Liposarcoma Phase 2
MDM2 Basket Study Phase 1a
AML: FLT3-ITD / Quizartinib Phase 1a
Tarloxotinib
Pan-HER
NSCLC: HER2 Ex20 Phase 2
Basket: NRG1 / HER Fusions1 Phase 2
RAD52 Research Program PARP-relapsed. HRD+Tumors Preclinical
BRCA-deficient tumors Preclinical

1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions